These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23720054)

  • 1. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.
    Itkonen HM; Minner S; Guldvik IJ; Sandmann MJ; Tsourlakis MC; Berge V; Svindland A; Schlomm T; Mills IG
    Cancer Res; 2013 Aug; 73(16):5277-87. PubMed ID: 23720054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells.
    Itkonen HM; Urbanucci A; Martin SE; Khan A; Mathelier A; Thiede B; Walker S; Mills IG
    Theranostics; 2019; 9(8):2183-2197. PubMed ID: 31149037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
    Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
    Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1.
    Caldwell SA; Jackson SR; Shahriari KS; Lynch TP; Sethi G; Walker S; Vosseller K; Reginato MJ
    Oncogene; 2010 May; 29(19):2831-42. PubMed ID: 20190804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism.
    Itkonen HM; Gorad SS; Duveau DY; Martin SE; Barkovskaya A; Bathen TF; Moestue SA; Mills IG
    Oncotarget; 2016 Mar; 7(11):12464-76. PubMed ID: 26824323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.
    Lynch TP; Ferrer CM; Jackson SR; Shahriari KS; Vosseller K; Reginato MJ
    J Biol Chem; 2012 Mar; 287(14):11070-81. PubMed ID: 22275356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
    Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
    Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients.
    Kamigaito T; Okaneya T; Kawakubo M; Shimojo H; Nishizawa O; Nakayama J
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):18-22. PubMed ID: 24366413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells.
    Devi GR; Oldenkamp JR; London CA; Iversen PL
    Prostate; 2002 Nov; 53(3):200-10. PubMed ID: 12386920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A long noncoding RNA connects c-Myc to tumor metabolism.
    Hung CL; Wang LY; Yu YL; Chen HW; Srivastava S; Petrovics G; Kung HJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18697-702. PubMed ID: 25512540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
    Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
    Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
    Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense glutaminase inhibition modifies the O-GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells.
    Donadio AC; Lobo C; Tosina M; de la Rosa V; Martín-Rufián M; Campos-Sandoval JA; Matés JM; Márquez J; Alonso FJ; Segura JA
    J Cell Biochem; 2008 Feb; 103(3):800-11. PubMed ID: 17614351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VPRBP Functions Downstream of the Androgen Receptor and OGT to Restrict p53 Activation in Prostate Cancer.
    Poulose N; Forsythe N; Polonski A; Gregg G; Maguire S; Fuchs M; Minner S; Sauter G; McDade SS; Mills IG
    Mol Cancer Res; 2022 Jul; 20(7):1047-1060. PubMed ID: 35348747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.
    Mink SR; Hodge A; Agus DB; Jain A; Gross ME
    Prostate; 2010 Aug; 70(11):1201-10. PubMed ID: 20564426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of O-Linked N-Acetylglucosamine Transferase Reduces Replication of Herpes Simplex Virus and Human Cytomegalovirus.
    Angelova M; Ortiz-Meoz RF; Walker S; Knipe DM
    J Virol; 2015 Aug; 89(16):8474-83. PubMed ID: 26041297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
    Hawksworth D; Ravindranath L; Chen Y; Furusato B; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):311-5. PubMed ID: 20820186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.